Semaglutide has a half-life of approximately seven days, which means weekly dosing maintains relatively steady concentrations
In December 2025, the FDA approved a daily pill version of Wegovy, giving needle-averse patients the first oral GLP-1 option cleared for obesity treatment
The overlap in claimed benefitsparticularly glucose controlcreates natural concern about safety
Prescribers should monitor mental health, particularly in patients with psychiatric histories
The GLP-1 user may want a high-protein, high-fiber snack, but they wont repurchase it if it doesnt taste good
To date, there are more than 2,100 lawsuits against Novo Nordisk, the makers of Ozempic and Wegovy, tied to NAION